BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Sartorius and MAbSilico Unite AI and Cell Line Development to Accelerate Biologics Discovery

Sartorius and MAbSilico are collaborating to connect Al-driven protein discovery with automated, high-throughput cell line development The integrate...

October 02, 2026 | News

Rznomics Secures Positive EMA Opinion for Orphan Designation of RZ-001 in Glioma

Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA...

October 02, 2026 | News

Piramal and NP2 Advance Generic Cancer Drug Cyclophosphamide Towards US Manufacturing

Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. The development and manufacturi...

October 02, 2026 | News

Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of Bispecific ADC TJ102

Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), announced that the first patient h...

October 02, 2026 | News

Health In Tech Launches AI-Powered HitRix Platform for Large-Group Health Insurance

AI-powered HitRix platform streamlines large-group submissions, multi-market quoting, proposal comparison and placement in one secure environment, thereby ...

October 02, 2026 | News

Piramal Pharma Invests $5.3M to Expand Drug Substance Manufacturing in Canada

Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure. With its investment throug...

October 01, 2026 | Analysis

Lilly’s Retatrutide Delivers 20.8% Weight Loss in Phase III Obesity and Type 2 Diabetes Trial

In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half...

October 01, 2026 | News

China Approves Jaypirca Across All Lines of Therapy for CLL/SLL

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

September 30, 2026 | News

Link Cell Therapies Begins Phase I Trial of Logic-Gated CAR-T Therapy for Kidney Cancer

LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD ...

September 30, 2026 | News

Hengrui Pharma Inks $2.6B Licensing Deal With Novo Nordisk for Oral GLP-1/GIP Therapy

HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total pot...

September 30, 2026 | News

iRegene Advances Off-the-Shelf Retinal Cell Therapy Into Clinical Trials in US and China

Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. iReg...

September 30, 2026 | News

Leo Cancer Care Advances Upright Radiation Therapy Experience for Children

Leo Cancer Care has announced plans to further invest in the treatment experience for children undergoing radiation therapy. Following the world's fi...

September 29, 2026 | News

Innovent Expands Global Phase III IBI363 Trial to Non-Squamous NSCLC

Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization...

September 29, 2026 | News

Akeso Enrols First Patient in Global Phase III Cadonilimab Trial for Advanced Gastric Cancer

Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating ...

September 29, 2026 | News

Stay Connected